Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Queensland
-
Auchenflower, Queensland, Australia, 4066
- Wesley Medical Research Limited
-
Maroochydore, Queensland, Australia, 4558
- Coastal Digestive Health
-
North Mackay, Queensland, Australia, 4740
- Coral Sea Clinical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing to participate in the clinical trial
- Able and willing to provide informed consent
- Stable ostomy (no revisions in the last 6 months)
- At least 19 years old
- Medically stable, but may be on medications for chronic conditions
Exclusion Criteria:
- Unable or unwilling to provide adequate informed consent
- Non-English speakers
- Clinically significant disease
- Women who are pregnant, intending to become pregnant, or breastfeeding
- Use of anti-diarrheal medicine
- Suffer gastroparesis
- Opioid use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1 LMN-201 Anti-toxin B VHH-1
|
Components of LMN-201
|
|
Experimental: Cohort 1 LMN-201 Anti-toxin B VHH-2
|
Components of LMN-201
|
|
Experimental: Cohort 1 LMN-201 Anti-toxin B VHH-3
|
Components of LMN-201
|
|
Experimental: Cohort 4 LMN-201 VHH 1, 2, 3
|
Components of LMN-201
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Presence of Capsules and/or Transit Markers in Ostomy Fluid by Visual Observation
Time Frame: Arrival (baseline), Predose (immediately before dosing), and up to 12 hours post dose.
|
Count of participants with the presence or absence of capsules and/or transit markers at each collection timepoint in ostomy fluid by visual observation.
|
Arrival (baseline), Predose (immediately before dosing), and up to 12 hours post dose.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Carl Mason, Lumen Bioscience, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CDI01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on C. Diff. Infections
-
NCT03497806CompletedClostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota
-
NCT00177775Terminated
-
NCT04626947TerminatedInflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | C. Diff. Infections
-
NCT03462459CompletedClostridium Difficile Infection | Recurrent Clostridium Difficile Infection | CDI | C.Difficile Diarrhea | C. Diff Colitis | C.Difficile Colitis
-
NCT06237452RecruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
NCT00563173UnknownChronic Hepatitis C Virus Infection
-
NCT02723084CompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
NCT04136405Active, not recruitingChronic Hepatitis c | Hepatitis C Virus Infection, Past or Present
-
NCT01221298CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1
-
NCT02493855CompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Clinical Trials on LMN-201 Anti-toxin B VHH-1
-
NCT05330182RecruitingClostridioides Difficile Infection
-
NCT05296772RecruitingLymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental
-
NCT01119742Terminated
-
NCT02134106WithdrawnBacteremia | Ventilator-associated Pneumonia | Healthcare-associated Pneumonia
-
NCT03388268CompletedDiarrhea | Clostridium Difficile Infection
-
NCT00280384Completed
-
NCT05144698RecruitingHead and Neck Cancer | Solid Tumor | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx | Small Cell and Non-small Cell Lung Cancer | Squamous Cell Carcinoma of Other Specified Sites of Skin
-
NCT05375903CompletedBladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder
-
NCT00005758Completed